Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Apollo Hospitals Q3...

    Apollo Hospitals Q3 profit rises 29 percent to Rs 86 crore on higher revenues

    GarimaWritten by Garima Published On 2019-02-12T09:15:29+05:30  |  Updated On 12 Feb 2019 9:15 AM IST
    Apollo Hospitals Q3 profit rises 29 percent to Rs 86 crore on higher revenues

    Apollo Hospitals on Saturday said that it plans to transfer the front-end retail pharmacy business carried out in the standalone pharmacy segment to a separate entity.


    New Delhi: Apollo Hospitals Enterprise (AHEL) has posted 29 per cent growth in net profit to Rs 86.93 crore during the quarter ended December 31, 2018, compared to Rs 67.44 crore during the same quarter of the previous financial year.


    Total income grew 16.8 per cent to Rs 2,046.75 crore during the quarter, as against Rs 1,864.13 crore during the corresponding quarter a year ago.


    Sanjay Nayar, member and CEO of KKR India — an Independent Director of the company since 2014 — has resigned from the board with effect from February 9. The company, in a regulatory filing, said that Nayar has expressed his inability to devote adequate time to the affairs of the company going forward, given his increased professional commitments. Company officials were immediately not available for comment. Nayar was appointed to the post with effect from February 10, 2014, after the US-based Private Equity player Kohlberg Kravis Roberts (KKR) has infused around Rs 550 crore in AHEL’s holding company PCR Investments in October 2013, which was expected to be used to repay promoters' debt and build more hospitals.


    The company on Saturday said that it plans to transfer the front-end retail pharmacy business carried out in the standalone pharmacy segment to a separate entity.


    By way of a slump, the sale has not been reflected in the results since the receipt of necessary approvals is pending.


    Also Read: Aurobindo Pharma Q3 profit rises 19.69 per cent to Rs 712 crore on robust sales
    ApolloApollo HospitalApollo Hospitals Enterpriseapollo profithospital newsindian hospital newsKKRKohlberg Kravis Robertspharmacy businessprofitQ3Sanjay Nayar
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok